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Abstract
Maternal obesity has a major impact on pregnancy outcomes. There is growing evidence
that maternal obesity has a negative influence on placental development and function,
thereby adversely influencing offspring programming and health outcomes. However, the
molecular mechanisms underlying these processes are poorly understood. We analysed
ten term placenta’s whole transcriptomes in obese (n = 5) and normal weight women (n = 5),
using the Affymetrix microarray platform. Analyses of expression data were carried out
using non-parametric methods. Hierarchical clustering and principal component analysis
showed a clear distinction in placental transcriptome between obese and normal weight
women. We identified 72 differentially regulated genes, with most being down-regulated in
obesity (n = 61). Functional analyses of the targets using DAVID and IPA confirm the
dysregulation of previously identified processes and pathways in the placenta from obese
women, including inflammation and immune responses, lipid metabolism, cancer pathways,
and angiogenesis. In addition, we detected new molecular aspects of obesity-derived
effects on the placenta, involving the glucocorticoid receptor signalling pathway and dysre-
gulation of several genes including CCL2, FSTL3, IGFBP1, MMP12, PRG2, PRL, QSOX1,
SERPINE2 and TAC3. Our global gene expression profiling approach demonstrates
that maternal obesity creates a unique in utero environment that impairs the placental
transcriptome.







Citation: Altmäe S, Segura MT, Esteban FJ, Bartel
S, Brandi P, Irmler M, et al. (2017) Maternal Pre-
Pregnancy Obesity Is Associated with Altered
Placental Transcriptome. PLoS ONE 12(1):
e0169223. doi:10.1371/journal.pone.0169223
Editor: Christopher Torrens, University of
Southampton, UNITED KINGDOM
Received: August 30, 2016
Accepted: December 13, 2016
Published: January 26, 2017
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Introduction
Maternal obesity has increased between 70–100% over the last decade [1]. This has had conse-
quences for different aspects of female reproduction, as maternal adiposity is related to an
increased risk of the majority of maternal and fetal complications [1]. Maternal pre-gravid
obesity has been associated with an increased risk of miscarriage, gestational diabetes, pre-
eclampsia, Caesarean section, instrumental vaginal delivery, birth trauma, stillbirth, and pelvic
floor damage [1,2]. Infants of overweight and obese mothers are at higher risk of being born
large for gestational age and/or macrosomic, and for developing obesity, cardiovascular dis-
ease, and diabetes in adulthood [2].
Being at the interface between the maternal and fetal environment, the placenta plays a
central role in how maternal obesity influences the programming of health outcomes in
the offspring. It has been shown that the placental structure and function is shaped by
obesity already at the early developmental stages and onward [3]. Furthermore, previous
studies demonstrate that obesity during pregnancy promotes a maternal environment
favouring increased inflammation, lipotoxicity, and oxidative stress in the placenta [4–6],
which may in turn alter maternal endothelial function [7], trophoblast invasion and differ-
entiation [7], vascular development and function [6], and placental nutrient transport [8].
The molecular mechanisms underlying these changes are poorly understood so far and
therefore further research in this field is warranted. Knowing the molecular bases of these
processes would provide valuable insights into the placental development and functions and
help to identify molecular mechanisms that have both immediate and long lasting effects on
fetal health.
With the recent evolution of ‘omics’ techniques, a number of genome-scale transcrip-
tional studies on normal human placenta have been performed and a unique placental
transcriptome has been identified [9–14]. However, the effects of maternal obesity on the
human placental transcriptome have received little attention, and only a few studies have
been published [3,5,6]. Saben et al. performed RNA-sequencing on term placentas from lean
and obese women and found dysregulation of genes related to lipid metabolism, angiogene-
sis, hormone activity and inflammation in placentas from obese women. This indicates that
the obese maternal environment may adversely affect placental development and function
[6]. Two other studies focused on the first trimester placental transcriptome using microar-
ray platforms [3,5]. Lassance et al. analysed the transcriptome of trophoblast cells of first tri-
mester placenta exposed in vitro to insulin and obesity. They concluded that maternal
obesity associated with insulin resistance programs the placental transcriptome towards
refractoriness to insulin with potential adverse effects for placental structure and function
[3]. Another study by Saben et al. identified several genes and signalling pathways in tropho-
blast cells following lipotoxic challenge, providing novel insights into the possible mecha-
nisms underlying obesity-induced placental inflammation [5]. Thus, there is only one
study to date that has directly investigated how maternal obesity influences the placental
transcriptome.
We therefore set out: (i) to investigate the transcriptome profile of term placentae in obese
women in comparison to normal weight women in order to provide further insights into the
molecular effects of maternal obesity on placental environment, and (ii) to find molecular bio-
markers/targets and candidate regulatory pathways dysregulated by maternal pre-pregnancy
obesity.
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Materials and Methods
Study subjects
Ten women participating in the PREOBE study were carefully selected for the current study.
The PREOBE study (Role of Nutrition and Maternal Genetics on the Programming of Devel-
opment of Fetal Adipose Tissue) is an observational cohort study on healthy normal weight,
overweight, and obese women, as well as women who developed gestational diabetes. This
study was performed at the Clinical University Hospital ‘San Cecilio’ and ‘Mother-Infant’
Hospital in Granada, Spain (the study has been registered at www.ClinicalTrials.gov, NLM
identifier: NCT01634464 2012) [15]. The project was approved by the Research Bioethical
Committee of the University of Granada, and all women signed written informed consent
after receiving the full information by a member of the research team.
Five normal weight women, whose pre-pregnancy body mass index (BMI kg/m2) was
between 18–25, and five obese women, whose BMI was30, were selected for this study. All
women were: with European descent, healthy, with age range between 25 and 35 years, had no
pregnancy complications or gestational diabetes, had normal blood pressure throughout preg-
nancy, were non-smoking, consumed no alcohol or drugs, had a normal pregnancy with fetal
development in accordance to the pregnancy week, fetal position was cephalic, had natural
term delivery, and had a normal/healthy placenta based on visual inspection. During preg-
nancy, routine pregnancy evaluation was performed at weeks 24, 34, and at delivery (see
Table 1 for clinical characteristics). Additionally, blood was collected for fatty acid analysis
during pregnancy and at delivery (the protocol for fatty acid analysis is described in our previ-
ous publication [16].
Collection of term placenta samples
Placenta samples were collected and weighed immediately after delivery by a well-trained
expert. Disc samples containing both maternal and fetal tissue were collected from identical
portions of the placental plate starting from the periphery of the maternal side in order to
avoid any regional variations. Next, after removal of the decidua, a 0.5 x 0.5 x 0.5 cm (200 mg)
sample was excised from the middle of the radius (distance between the insertion of the umbil-
ical cord and the periphery) of each placenta. Each sample was then rinsed twice with saline
solution (NaCl 0.9%), and immediately placed into sterile 1.5 ml microtubes containing RNA-
later solution (Quiagen, Venlo, The Netherlands). All samples were stored under RNase free
conditions at -80˚C for later analysis at the Comprehensive Pneumology Center Munich.
Total RNA isolation and microarray hybridisation
For microarray and real-time PCR analysis, total RNA was isolated from the placental samples
by using the miRNeasy mini kit (Quiagen) according to the manufacturer’s instructions. RNA
concentration was calculated with a Nanodrop-1000 spectrophotometer (NanoDrop Fluorom-
eter, Thermo Scientific, Wilmington, DE, USA). Only the highest quality RNA (260/280
ratio > 1.8, no degradation as detected by RNA agarose gel) was used for microarray analysis.
70% of the RNA samples were further analysed with Bioanalyzer (A2100 Bioanalyzer, Agilent
Technologies). An RNA integrity value (RIN) of7.0 was considered acceptable.
Thirty ng of total RNA was amplified using the Ovation PicoSL WTA System V2 in combi-
nation with the Encore Biotin Module (NuGEN Technologies, Inc, San Carlos, CA, USA).
Amplified cDNA was hybridized on Affymetrix human Gene ST 2.0 arrays containing about
50,000 probe sets (Affymetrix, Santa Clara, CA, USA). Staining (Fluidics script FS450_00002)
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and scanning was done according to the Affymetrix expression protocol including minor
modifications as suggested in the Encore Biotin protocol (NuGEN Technologies, Inc).
Microarray data analysis
Pre-processing and differential gene expression. Expression console (v.1.2, Affymetrix)
was used for quality control and to obtain annotated normalized RMA gene-level data (stan-
dard settings including median polish and sketch-quantile normalisation).
Data analyses were performed using the R-statistical software system (Free Software Foun-
dation, Boston, USA). Gene expression profiles were determined by comparing the obese and
normal weight groups (2 by 2 comparisons) by means of the rank product non-parametric test
in the Bioconductor RankProd package (www.bioconductor.org/packages/devel/bioc/html/
RankProd.html). Due to the limited number of samples, a non-parametric statistical test was
used as a rough filter to narrow down the list of the most relevant genes. The statistics calcu-
lated is equivalent to the geometric mean rank and it is less sensitive to outliers. Additionally,
the proportion of false positives (PFP) correction was used to control errors in multiple tests,
as it effectively controls the accumulation of false-positives relative to the total number of posi-
tive results [17]. A PFP of<0.05 was considered statistically significant.
Table 1. Clinical characteristics of the participating women in the study and their perinatal outcomes.
Normal weight (n = 5) Obese (n = 5) p-value
Maternal age (y) 30.2±1.9 29.8±4.6 NS
Parity (1)a 1 (20%) 4 (80%) NSb
Height (m) 1.68±0.02 1.63±0.02 <0.01
Weight (pre-pregnancy)(kg) 59.6±5.7 89.3±6.4 <0.01
BMI (pre-pregnancy)(m/kg2) 21.0±2.0 33.6±2.0 <0.01
Weight at 24 weeks (kg) 66.3±6.0 91.5±4.3 <0.01
Weight at 34 weeks (kg) 71.2±7.8 93.8±5.4 0.02
Weight at delivery (kg) 72.0±9.8 97.5±11.0 0.03
BMI at week 24 (m/kg2) 23.4±2.1 34.4±1.4 <0.01
BMI at week 34 (m/kg2) 25.1±2.8 35.2±1.2 0.02
BMI at delivery (m/kg2) 25.2±3.3 36.7±3.6 0.03
Weight gain until week 34 (kg) 11.6±4.9 5.1±4.2 0.06
Total weight gain during pregnancy 12.5±6.7 6.8±6.9 NS
Gestational age at delivery (weeks) 38.8±0.8 39.7±1.3 NS
Placenta weight (g) 472±122 562±84 NS
Placental/fetal -ratio 0.14±0.04 0.16±0.03 NS
Apgar score at 5 min 10±0 10±0 NS
Infant gender (boy)a 3 (60%) 4 (80%) NSb
Birth weight (g) 3344±302 3602±595 NS
Newborn birth length (cm) 49.6±1.5 51.2±2.7 NS
Newborn BMI (m/kg2) 13.6±0.9 13.7±1.4 NS
Newborn head circumference (cm) 35±0.7 35.2±2.1 NS
Newborn waist circumference (cm) 32.2±1.0 34.6±4.1 NS
Newborn waist/height index 0.64±0.03 0.68±0.07 NS
Data is presented as mean±SD or an (%), and p-values are non-parametric Mann-Whitney U-test or bChi
square test. NS—statistically non-significant difference between groups. BMI—Body Mass Index
doi:10.1371/journal.pone.0169223.t001
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Our primary microarray data are available in the public database ArrayExpress (www.ebi.
ac.uk/arrayexpress) under accession number E-MTAB-4541. Two samples did not pass the
stringent Model Based Quality Control Assessment of Affymetrix GeneChips, which was car-
ried out using the corresponding affyPLM package (https://bioconductor.org/packages/
release/bioc/html/affyPLM.html). Briefly, the Normalized Unscaled Standard Errors (NUSE)
function was run over the data. This process accounts for differences in variability between
genes based on standard error (SE) estimates obtained for each gene on each array; any given
array with elevated SE relative to the other arrays is considered of lower quality. The final anal-
yses were performed in total on 8 samples (4 in each group).
Sample clustering and principal component analysis. In order to validate the above
gene selection with a non-parametric method, a principal component analysis (PCA) and a
hierarchical clustering were performed using MeV 4.2.02 software (www.tm4.org) [18]. In
PCA analysis, a three-dimensional scatter plot was produced in order to visualize the differ-
ences between the sample sets based on each sample’s gene expression profile. The method
used to calculate the distance was the covariance and the number of probes that differentially
expressed genes. In the hierarchical clustering, the data were Z-normalized by gene and the
Euclidean distance was selected as the similarity to cluster expression profiles. The method
used to perform the linkage was a complete-linkage hierarchical clustering algorithm.
Enrichment analysis of the results. Enrichment analysis of differentially regulated genes
was explored by using the Database for Annotation, Visualization and Integrated Discovery
(DAVID, v. 6.7) [19] and gProfiler [20], and Ingenuity Pathways Analysis (IPA1) (Ingenuity1
Systems, www.ingenuity.com, release date 09.12.2014). DAVID searches blocks of functionally
related genes according to different criteria such as the Gene Ontology (GO) terms as biologi-
cal process, cellular component and molecular function. GO FAT search was used in order to
filter the broadest terms so that they do not overshadow the more specific terms (david.abcc.
ncifcrf.gov). Further enrichment analyses, including canonical pathways and networks of
dysregulated genes were analysed with IPA. A multiple testing correction, false discovery
rate (FDR) was applied, and FDR<5.0% and a p-value <0.05 were considered statistically
significant.
Microarray validation by real-time PCR
In order to validate the microarray results, 500ng of the same RNA samples were reverse-tran-
scribed using the Quantitect Reverse Transcription kit according to the manufacturer’s recom-
mendations (Qiagen, Venlo, Netherlands). The obtained cDNA was diluted 10x in PCR-grade
water for qRT-PCR analysis.
The genes AREG, CCL2, FSTL3, IGFBP1 andMMP12were used for microarray validation.
Specific forward and reverse primer pairs were designed for each gene and are listed in
Table A in S1 File. Real-time qPCR was performed on the Roche Light Cycler II platform with
the Roche Light Cycler 480 SYBR Green I Master mix (Roche, Mannheim, Germany). The
final products were verified by melting curve analysis by using the provided software (Roche,
Mannheim, Germany). Data are presented as dCp values (Cptargetgene-Cpreferencegene), where
higher dCp values represent lower expression; while graphs are represented on reversed Y-
axes. B2M and YWHAZ where used as reference genes. We tested 8 different housekeeping
genes that have been used in studies of human placenta (by [21] and others) for our study:
SDHA, B2M, ACTB, BRD1,KCTD2,HPRT, YWHAZ and TBP. B2M and YWHAZ genes were
the most suitable for our study as they showed the lowest variation among subjects and groups.
The geometric mean of B2M and YWHAZ Ct values was used for normalisation. The analysis
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of gene expression differences between the study groups was performed using the Mann-Whit-
ney U-test. P-values of<0.05 were considered statistically significant.
Results
Characteristics of participating subjects
The perinatal outcomes between normal weight and obese women did not differ significantly.
However, the mean weight of the placenta, as well as the newborn’s birth weight and length,
head circumference, waist circumference, and BMI were somewhat bigger/higher in obese
women than normal weight women (Table 1).
The analysis of plasma fatty acids at pregnancy weeks 24 and 34 demonstrated significant
differences in palmitic acid, oleic acid and arachidonic acid concentrations between the study
groups (fatty acid values are expressed as percentages by weight, wt %. See Table B in S1 File).
At pregnancy weeks 24 and 34 palmitic acid was significantly higher in obese women when
compared to normal weight women (33.7±0.6 vs. 30.5±1.0, p = 0.016; and 34.3±0.7 vs. 32.2
±1.1, p = 0.032). Oleic acid was significantly lower (10.7±1.0 vs. 13.0±1.8, p = 0.032) and ara-
chidonic acid was significantly higher (9.7±0.2 vs. 7.9±1.4, p = 0.016) in plasma of obese
women when compared to normal weight women at pregnancy week 34.
Cluster analysis of microarray data
The PCA analysis demonstrated a very clear separation of placental gene expression profiles
between obese and normal weight women (Fig 1A). In addition, hierarchical clustering was
applied to the microarray data and a similar pattern was obtained, where two study groups
clustered into two different groups (Fig 1B).
Differential gene expression analysis of term placenta from obese vs.
normal weight women
A total of 72 differentially regulated genes were identified. Eleven transcripts were up-regu-
lated and 61 genes were down-regulated in term placentas of obese vs. normal weight women
(see Table 2). Interestingly, the majority of the differentially regulated genes were down-regu-
lated (84.7%), while only 15.3% of the genes were up-regulated in the placentas of obese
women.
GO analysis of differentially regulated genes revealed that a significant proportion of the
genes in the placentae of obese women vs. normal weight women were involved in carbohy-
drate binding (11.5%, p = 0.009), and more specifically in polysaccharide (9.8%, p = 0.001)
and heparin binding (8.2%, p = 0.003). A large proportion of the differentially regulated genes
were located in the extracellular region (49.2%, p<0.0001).
To obtain insight into relevant biological processes we used IPA analysis, and found that
differentially regulated placental gene expression in obese women involved pathways concern-
ing crosstalk between dendritic cells and natural killer cells, hepatic fibrosis/hepatic stellate cell
activation, UPD-D-xylose and UPD-D-glucuronate biosynthesis, inhibition of matrix metallo-
proteases, atherosclerosis signalling among several others (Fig 2).
Analysis of the molecular relationships between differentially expressed genes showed two
complex networks where the majority of signals were mediated through ERK, IgG, NFKB, and
MAPK complexes (Fig 3A), and through TGFB, MYC and TP53 complexes (Fig 3B). The high-
est scoring IPA network of the molecular relationships between differentially expressed genes
revealed the involvement of the molecules in top diseases and functions such as embryonic
development, organismal development, and cancer, where different genes including: AREG,
Placental Transcriptome in Obesity
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CCL2, FN1,HLA-DRB1, IGFBP1, IL1R2,MMP12, PRL, and TNFSF10were intertwining (IPA
score of 46; Fig 3A). The second largest network of genes were involved in cellular movement,
haematological system development and function, as well as immune cell trafficking, where
different genes such as those for ADAM19,AOC1, IL2RB, PLAC8, SERPINE2, SP1 and others
seem to play important roles (IPA score of 23; Fig 3B).
The IPA Upstream Regulator Analysis identified two potential upstream regulators with a
significant activation score (z-score|2|) among the dysregulated genes in placentas of
obese vs. normal weight women. IgG was predicted to be an activated upstream regulator
(z-score = 2.0, p = 0.0004), with CCL2,CRABP2,GPRC5A, LGALS3 as known target molecules.
The second potential upstream regulator was ERBB2, being inhibited (z-score = -2.0, p =
0.002), with genes ADAM19,CGB8, FN1, and FSTL3 as downstream targets.
Microarray validation
Real-time PCRs using genes AREG, CCL2, FSTL3, IGFBP1 andMMP12 confirmed the array
results. CCL2was significantly up-regulated, and IGFBP1 andMMP12were significantly
down-regulated (Fig 4). AREG and FSTL3 genes expression profiles between obese and normal
Fig 1. (A) Principal component analysis (PCA) of term placental gene expression profiles in obese (Ob_ N˚) and normal weight women
(N_N˚). (B) Cluster analysis of dysregulated genes in term placentas from obese (Ob_ N˚) vs. normal weight women (N_N˚). Red represents
genes with high expression levels and green represents genes with low expression levels.
doi:10.1371/journal.pone.0169223.g001
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Table 2. List of dysregulated genes in term placentas from obese women vs. normal weight women. The genes identified in previous transcriptome
studies in human placentas in health and disease are indicated.




CCL2 Chemokine ligand 2 Cytokine. Immune and inflammatory response 2.77 0.00 [9]
RN5S363 RNA, 5S ribosomal pseudogene 363 Unknown 2.72 0.02
RNY4P17 RNA, Ro-associated Y4 pseudogene 17 Unknown 2.69 0.01
RN5S220 RNA, 5S ribosomal pseudogene 220 Unknown 2.63 0.01
GRIK1-AS2 GRIK1 antisense RNA 2 Transcription factor 2.43 0.01
HLA-DRB1 Major histocompatibility complex, class II,
DR beta 1
Immune response 2.32 0.04 [9]
AREG Amphiregulin Growth factor. Promotes growth of epithelial cells.
Cancers and inflammatory conditions
2.15 0.02
DND1 DND1 microRNA-mediated repression
inhibitor 1
Inhibits microRNA-mediated repression. Cancer. 2.10 0.05
SNORA10 Small nucleolar RNA, H/ACA box 10 Unknown 2.08 0.04
STARD10-AS1 STARD10 antisense RNA 1 Unknown 2.01 0.04
RNF144B Ring finger protein 144B Apoptosis 1.88 0.04 [9]
ERAP2 Endoplasmic reticulum aminopeptidase 2 Immune response -1.91 0.04 [22]
C12orf75 Chromosome 12 open reading frame 75 Unknown -1.91 0.03 [23]
MGAT5 Mannosyl-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase
Enzyme. Biosynthesis of glycoprotein oligosaccharides -1.93 0.04
LGALS3 Lectin, galactoside-binding, soluble, 3 Immune response, apoptosis, cell adhesion -1.94 0.03 [9,12]
PIPOX Pipecolic acid oxidase L-lysine catabolic process, tetrahydrofolate metabolic
process
-1.95 0.04 [9]
ADAM19 ADAM metallopeptidase domain 19 Cell migration and adhesion. Cancer, inflammatory
diseases
-1.97 0.04
CERS6 Ceramide synthase 6 Ceramide biosynthetic process, shpingolipid metabolic
process
-1.99 0.05
DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide
46
Pre-mRNA splicing -1.99 0.03
TIMP3 TIMP metallopeptidase inhibitor 3 Negative regulation of endopeptidase activity -2.03 0.03 [9,10]
FSTL3 Follistatin-like 3 Cell differentiation, development -2.03 0.03 [9,14,24–27]
PDE10A Phosphodiesterase 10A Signal transduction, blood coagulation -2.04 0.02
RBP4 Retinol binding protein 4, plasma Retinol carrier in the blood. Developmental processes -2.07 0.04 [25]
ABI3BP ABI family, member 3 binding protein Collagen and heparin binding -2.08 0.02 [12]
LOC100508885 Uncharacterised LOC100508885 Unknown -2.11 0.01
CRABP2 Cellular retinoic acid binding protein 2 Retinoid signalling pathway. Development -2.12 0.02 [9]
GPRC5A G protein-coupled receptor, class C,
group 5, member A
Retinoid acid and G protein signalling pathways.
Development, growth and differentiation processes
-2.12 0.01
AOC1 Amine oxidase, copper containing 1 Metal-binding membrane glycoprotein that oxidatively
deaminates putrescine, histamine
-2.13 0.01
CCDC144A Coiled-coil domain containing 144A Unknown -2.17 0.03 [9]
PLAC8 Placenta-specific 8 Defence response -2.17 0.01 [9,10,12]
TSIX TSIX transcript, XIST antisense RNA Unknown -2.17 0.00
QSOX1 quiescin Q6 sulfhydryl oxidase 1 Growth regulation -2.20 0.01 [9,14]
HN1 Haematological and neurological
expressed 1
Cancer -2.21 0.01 [9,12,25]
REPS2 RALBP1 associated Eps domain
containing 2
Inhibits growth factor signalling, cancer -2.21 0.01
CGB8 Chorionic gonadotropin, beta polypeptide
8
Produced in placenta and stimulates steroid synthesis
in ovaries
-2.23 0.01 [9]
MIR374B MicroRNA 374b Gene expression regulation -2.24 0.05
(Continued )
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ADAM28 ADAM metallopeptidase domain 28 Cell-cell and cell-matrix interactions, fertilization, muscle
development, neurogenesis
-2.24 0.01 [9]
TNFSF10 Tumor necrosis factor superfamily,
member 10
Cytokine, induces apoptosis -2.25 0.01 [5,9,11,25]
SERPINE2 Serpin peptidase inhibitor, clade E,
member 2
Negative regulation of blood coagulation, cell growth -2.27 0.01 [10,14]
GLIPR1 GLI pathogenesis-related 1 Cellular lipid metabolic process, cancer -2.30 0.01 [9,12]
IL2RB Interleukin 2 receptor, beta IL2 binding, immune response -2.31 0.01 [9,10,12]
SMYD3-IT1 SMYD3 intronic transcript 1 Unknown -2.32 0.01
UPK1B Uroplakin 1B Cell development, activation, growth and motility -2.35 0.02 [23]
FOSB FBJ murine osteosarcoma viral oncogene
homolog B
Regulator of cell proliferation, differentiation,
transformation
-2.38 0.01 [13,24]
OMD Osteomodulin Carbohydrate metabolism, cell adhesion -2.38 0.01
UBL3 Ubiquitin-like 3 Unknown -2.40 0.00
UGDH UDP-glucose 6-dehydrogenase Biosynthesis of glycosaminoglycans. Signal
transduction, cell migration, cancer growth
-2.43 0.01 [9,12]
HSD11B1 Hydroxysteroid dehydrogenase 1 Enzyme catalysing cortisol to cortisone. Obesity, insulin
resistance
-2.47 0.01 [9,25]
SLPI secretory leukocyte peptidase inhibitor Immune response -2.48 0.01 [9]
NOTCH2NL Notch 2 N-terminal like Notch signalling pathway, cell differentiation -2.51 0.02 [9]
DNAPTP3 Histone demethylase UTY-like Unknown -2.52 0.00
FN1 Fibronectin 1 Cell adhesion and migration, embryogenesis, wound
healing, host defence, cancer
-2.55 0.00 [23]
IL1R2 Interleukin 1 receptor, type II Immune response -2.56 0.00 [9,12,25]
EPYC Epiphycan Fibrillogenesis, pregnancy -2.60 0.01 [25]
PAEP Progestagen-associated endometrial
protein
Regulates uterine environment for pregnancy,
organismal development
-2.65 0.01 [9]
GKN1 Gastrokine 1 Positive regulation of cell division and proliferation.
Cancer
-2.68 0.00
RN5S457 RNA, 5S ribosomal pseudogene 457 Unknown -2.74 0.01
LOC728643 Heterogeneous nuclear ribonucleoprotein
A1 pseudogene
-2.79 0.00
HTRA4 HtrA serine peptidas 4 Cell growth regulation -2.90 0.00 [9,25]
NOTUM Notum pectinacetylesterase homolog Unknown -3.01 0.00 [9]
PLA2G7 Phospholipase A2, group VII Lipid catabolic process, positive regulation of
inflammatory response
-3.12 0.00 [9,12]
RN5S395 RNA, 5S ribosomal pseudogene 395 Unknown -3.16 0.00
DKK1 Dickkopf WNT signalling pathway inhibitor
1
Embryonic development through inhibiting WNT
signalling pathway
-3.46 0.00 [6,9,12]
XIST X inactive specific transcript X chromosome inactivation -3.56 0.00 [10]
LAIR2 Leukocyte-associated immunoglobulin-
like receptor 2
Immune response, inhibition of platelet aggregation and
vessel formation during placental implantation
-3.95 0.00 [9]
PRL Prolactin Hormone, growth factor, immune response, supresses
apoptosis, essential for lactation
-3.98 0.00 [24]
MMP12 Matrix metallopeptidase 12 Embryonic development, reproduction, tissue
remodelling, inflammation, cancer
-4.00 0.00 [9,27]
SNORD14E Small nucleolar RNA, C/D box 14E Unknown -4.22 0.00
CHRDL1 Chordin-like 1 Eye development, BMP signalling pathway -4.37 0.00
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weight women did not reach statistical significance (p>0.05), nevertheless we observed a trend
towards a similar dysregulation compared to the microarray.
Discussion
We report the genome-wide transcriptome analysis of the effects of maternal obesity on the
term placenta, in the absence of gestational diabetes and other complications. Our study results
demonstrate that maternal pre-pregnancy obesity has adverse effects on the placental tran-
scriptome, where previously characterised molecules and molecular pathways involved in
placental development and function [14] were dysregulated. In addition, several new dysregu-
lated molecules and signalling pathways were identified.
It is now well established that maternal obesity is associated with a pro-inflammatory milieu
during pregnancy and in the placenta, [5,6]. In line with that, obese women in the present
study had significantly higher plasma levels of arachidonic acid (which is involved in inflam-
matory processes) at pregnancy week 34. It has been demonstrated in mice that obesity during
pregnancy disrupts inflammation through increased macrophage activation and elevation of
cytokine gene expression, which provides potential links between placental inflammation and
the programming of offspring disease by maternal obesity [29]. Furthermore, the majority of
the identified dysregulated genes in our study including CCL2,HLA-DRB1, IL1R2, IL2RB,
TNFSF10, FN1, andMMP12 are involved in inflammation and immune responses, and the sec-
ond biggest network of the dysregulated genes being involved in immune cell trafficking. We
also identified immunoglobulin G (IgG) as an upstream activator of several dysregulated genes
(CCL2,CRABP2,GPRC5A, LGALS3) in placentas from obese women. IgG is the main type of
antibody found in blood and extracellular fluid that controls infection in body tissue by medi-
ating pro- and anti-inflammatory activities [30].
Lipid metabolism is another process that has shown to be altered in placentas from obese
women [6,7]. Our obese women demonstrated different palmitic acid and oleic acid levels in
the plasma at pregnancy weeks 24 and 34 when compared to normal weight women, support-
ing altered lipid metabolism. Furthermore, functional analyses of our microarray data identi-
fied lipid and cholesterol metabolism, specifically the LXR/RXR activation pathway to be
dysregulated among placentas from obese women. The importance of liver X receptors (LXRs)
in physiological lipid and cholesterol metabolism suggests that they are involved in the devel-
opment of metabolic disorders such as hyperlipidaemia (lipotoxicity) and atherosclerosis [31].
Indeed, a recent study concluded that maternal obesity leads to a lipotoxic placental environ-
ment that is associated with decreased regulators of angiogenesis and increased markers of
inflammation and oxidative stress [6].
Another interesting finding in our study was that all analyses indicated that obesity influ-
ences cancer pathways. The detection of cancer pathways among placental gene expression is
not surprising, as many proliferative, invasive, and immune tolerance mechanisms that sup-
port normal pregnancy are also exploited by malignancies [12,32]. Furthermore, we identified
erb-b2 receptor tyrosine kinase 2 (ERBB2) as an upstream inhibitor of several genes including
Table 2. (Continued)




PRG2 Proteoglycan 2, bone marrow High levels in placenta, defence mechanisms and
immune response
-6.55 0.00 [9]
IGFBP1 Insulin-like growth factor binding protein 1 Insulin receptor signalling pathway, positive regulation
of cell growth, tissue regeneration
-10.27 0.00 [12,24–27]
doi:10.1371/journal.pone.0169223.t002
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Fig 2. The Circos plot represents significantly enriched pathways associated with regulated genes in the placentae of obese
women vs. normal weight women, detected using the Ingenuity Pathway Analysis library of canonical pathways. Outside the
circle dysregulated genes and IPA pathways together with biological process are indicated. All genes are down-regulated (highlighted
in green), except for HLA-DRB1 and CCL2 genes that are up-regulated (highlighted in red).
doi:10.1371/journal.pone.0169223.g002
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ADAM19,CGB8, FN1, and FSTL3. ERBB2 is involved in the mitogen-activated protein kinase
signalling pathway and its role in cancer development and evolution has been shown [33].
In line with the similarities in pregnancy and cancer pathways, we detected haematological
system development and function in network analysis, and angiogenesis as important biologi-
cal processes affected by the dysregulated genes in placentas from obese women. Angiogenesis
is a crucial process for fetomaternal exchanges and placental development, and alterations in
this are associated with different pregnancy-related pathologies [34]. This is in accordance
with a previous study that has detected altered regulation of genes related to angiogenesis in
placentas from obese women [6].
A new observation in our study was the dysregulation of glucocorticoid receptor signalling
pathway in placentas from obese women, where expression of genes CCL2, IL1R2, PRL, and
SLPI were altered. Obesity has been associated with reduced sensitivity to glucocorticoid feed-
back, an effect believed to be mediated via altered sensitivity to the glucocorticoid receptor
[35]. Glucocorticoid receptor signalling is regulating genes controlling the development,
metabolism and immune responses, and is also involved in major organ systems physiology
and pathophysiology in the human body. Its important role during gestation for postnatal sur-
vival as well as during embryonic development has been shown in different animal studies
[35].
Another important finding in the search of obesity-related effects on term placentas was the
identification of several potential target molecules that could have important roles in under-
standing how the placenta affects fetal development and obesity-derived offspring’s future
health problems. We detected dysregulation in several genes that have been shown to play a
role in the function of normal placental development in humans, including AREG [36], CCL2
Fig 3. Shows the two highest scoring networks in IPA derived from the analysis of dysregulated genes in placentas of obese
women vs. normal weight women. (A) Genes involved in embryonic development, organismal development and cancer. (B) Dysregulated
genes involved in cellular movement, haematological system development and function, and immune cell trafficking. The intensity of the
node colour indicates the degree of up- (red) or down- (green) regulation of gene expression. A white node represents a gene that is not part
of our dataset, but is incorporated into the network through relationships with other genes. Nodes are displayed using various shapes that
represent the functional class of the gene product, and a biological relationship between two nodes is represented as a line. Detailed
information about the figure symbols can be found at www.ingenuity.com.
doi:10.1371/journal.pone.0169223.g003
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[37], FOSB [38], GKN1 [39], SERPINE2 [40], SLPI [41], and XIST [42]. In addition, several of
the identified dysregulated genes, including CCL2,CGB8, FOSB, FSTL3,HSD11B, IGFBP1,
PRL, RBP4, and TAC3 have been implicated in adverse pregnancy outcomes such as intrauter-
ine growth restriction [23,25,26,28], large for gestational age [24], and recurrent miscarriage
[43]. Furthermore, a set of the dysregulated genes has been associated with the risk of develop-
ing pre-eclampsia, including c12orf75 [23], DKK1 [44], FSTL3 [27], HTRA4 [45], IGFBP1 [27],
LAIR2 [27],MMP12 [27], PAEP [27], and UPK1B [23]. Especially interesting and promising
target molecules for obesity-derived implications in placenta could be CCL2, PRL,MMP12,
TAC3, PRG2 and IGFBP1 that were the most dysregulated genes among our study group.
Additionally, genes FSTL3,QSOX1 and SERPINE2 could serve as novel obesity-related bio-
markers, as they have been shown to be uniquely enriched in the placenta [14], and we
detected them as down-regulated among the placentas from obese women. All of these genes
could serve as molecular biomarkers for potential progression towards metabolic syndrome in
children that were born to overweight mothers.
A potential weakness of our and similar studies [5,10,11,22] is the small sample size. None-
theless, cluster analyses showed a very clear separation between the groups in the present
study. In addition, we have applied stringent non-parametric data analysis. Our study was
strengthened by the well selected and characterised homogenous study groups, where healthy,
Fig 4. Microarray validation by real-time PCR. The expression levels of genes AREG, CCL2, FSTL3, IGFBP1 and MMP12 from our gene
array analysis in comparison with real-time PCR gene expression levels are presented. QRT-PCR data are shown as dCp values
(Cptargetgene-Cpreferencegene), where higher dCp values represent lower expression and therefore, graphs are represented with reversed Y-
axis. Mann-Whitney U-test *p <0.05, n = 5 samples/group.
doi:10.1371/journal.pone.0169223.g004
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young, non-smoking, Spanish women with no pregnancy complications and with natural
delivery were enrolled.
Conclusions
The placental metabolic abnormalities resulting from the effects of maternal obesity (e.g. lipo-
toxicity) may be transmitted to the offspring via in utero programming and hence there could
be far-reaching consequences for offspring health. Management of maternal body weight and/
or manipulation of lipid metabolism using both lifestyle and pharmacological interventions
may provide benefits to the obese women as well as to their offspring. In fact, it has been
shown that maternal weight loss by pre-pregnancy bariatric surgery prevented transmission of
obesity to offspring compared with children of obese mothers who did not undergo this sur-
gery [46]. Further improvements/intervention programs in maternal weight control (prefera-
bly before pregnancy [47]) would improve perinatal metabolic outcomes.
Our findings provide a fundamental resource for better understanding the complex effects
of maternal pre-pregnancy obesity on placental transcriptome. We have detected new molecu-
lar aspects of obesity-derived effects on placentas, where the glucocorticoid receptor signalling
pathway and dysregulation of several genes including CCL2, FSTL3, IGFBP1,MMP12, PRG2,
PRL, QSOX1, SERPINE2 and TAC3 might have important roles. Our study also confirms the
dysregulation of previously identified important processes and pathways among placentas
from obese women. This global gene expression profiling approach demonstrates and con-
firms that maternal obesity creates a unique in utero environment that impairs the placental
transcriptome. Further elucidation of normal and aberrant placental ‘ome’ regulation will
not only increase our understanding of the origins of a disease, but may also provide novel
approaches for intervention.
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